
As Medicare negotiation, PBM reform, and cash-pay channels converge, winning on auditable net value matters more than cutting list prices.
As Japan prices take on greater global significance, disciplined launch strategy can help pharma companies capture the full value of innovation.
Japan launch pricing has become more consequential against the backdrop of the U.S. most-favored-nation (MFN) policy. Japan is included in the reference basket contemplated under several MFN models, meaning a low launch price can affect pricing well beyond the domestic market.






